Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

Shockwave Medical launches new IVL catheter for challenging lesions in Europe
The balloon-free catheter, which already had a successful launch in the United States, has been associated with positive outcomes and the ability to reach certain lesions more accurately than balloon-based IVL platforms.
FDA clears Apple Watch algorithm for detecting hypertension
The FDA’s decision arrived just days after Apple announced the new feature. "This tool empowers patients and clinicians to work together, putting prevention at the center of care," one cardiologist told Cardiovascular Business.
Update: FDA confirms recalls for defibrillation leads after nearly 400 injuries
Safety concerns with certain Boston Scientific leads have resulted in multiple Class I recalls, the FDA has announced. The agency first shared a warning about this issue in August.
Dexcom issues new recall for CGM apps due to safety risk—users urged to update immediately
The FDA has categorized this as a Class I recall. If patients update their phone or watch apps as needed, they can continue to use these devices like normal.
Cardiologist sues hospital after he was allegedly let go for sharing safety concerns
The veteran interventional cardiologist claims he was pushed out after repeatedly asking for more coverage from cardiothoracic surgeons in addition to other improvements. The hospital, meanwhile, described the lawsuit as a “collection of false allegations."

The final decision between ViV TAVR and repeat SAVR, researchers said, should be based on multiple factors.

Boston Scientific had already been a strategic investor in Devoro Medical since 2019, holding an equity stake in the company of approximately 16%.

Nearly 9,000 devices distributed in 2019 and 2020 are included in this Class 1 recall.

The society said it has no plans, as of yet, to add new safeguards following the Biden administration's announcement on Monday.

Researchers analyzed data from more than 17,000 participants, reviewing their findings in the American Journal of Cardiology.

Researchers examined data from 17 different facilities, keeping a close eye on mortality and rehospitalization rates.

“AFib remains a serious arrhythmia, and additional treatment options are needed,” one cardiologist said.

Nearly 6% of transplant recipients developed cancer within 10 years of the procedure, researchers reported.